Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Receivables (2018 - 2025)

Denali Therapeutics (DNLI) has disclosed Receivables for 8 consecutive years, with $1.6 million as the latest value for Q4 2025.

  • Quarterly Receivables fell 26.3% to $1.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.6 million through Dec 2025, down 26.3% year-over-year, with the annual reading at $1.6 million for FY2025, 26.3% down from the prior year.
  • Receivables for Q4 2025 was $1.6 million at Denali Therapeutics, down from $1.9 million in the prior quarter.
  • The five-year high for Receivables was $16.8 million in Q2 2021, with the low at $357000.0 in Q2 2022.
  • Average Receivables over 5 years is $2.8 million, with a median of $1.9 million recorded in 2024.
  • The sharpest move saw Receivables surged 5495.0% in 2021, then tumbled 97.87% in 2022.
  • Over 5 years, Receivables stood at $1.2 million in 2021, then tumbled by 70.88% to $357000.0 in 2022, then surged by 656.3% to $2.7 million in 2023, then decreased by 19.59% to $2.2 million in 2024, then fell by 26.3% to $1.6 million in 2025.
  • According to Business Quant data, Receivables over the past three periods came in at $1.6 million, $1.9 million, and $1.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.